Shu-hui Lv

State Key Laboratory Of Oncology In South China, Guangdong Key Laboratory Of Nasopharyngeal Carcinoma Diagnosis And Therapy
Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Induction Paclitaxel-Cisplatin-Capecitabine for Nasopharyngeal Carcinoma.

Induction Paclitaxel-Cisplatin-Capecitabine for Nasopharyngeal Carcinoma.

Journal: NEJM evidence

Published: August 25, 2026

Efficacy of radiotherapy to metastatic lesion in de novo metastatic nasopharyngeal carcinoma patients: A multicenter, propensity score matching study.

Efficacy of radiotherapy to metastatic lesion in de novo metastatic nasopharyngeal carcinoma patients: A multicenter, propensity score matching study.

Journal: Oral oncology

Published: December 14, 2025

Efficacy of metastatic lesion radiotherapy in de novo metastatic nasopharyngeal carcinoma patients receiving local regional radiotherapy and chemo-immunotherapy: a multicenter retrospective study.

Efficacy of metastatic lesion radiotherapy in de novo metastatic nasopharyngeal carcinoma patients receiving local regional radiotherapy and chemo-immunotherapy: a multicenter retrospective study.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: June 24, 2025

Capecitabine combined with immunotherapy as maintenance therapy improves survival in recurrent/metastatic nasopharyngeal carcinoma: a retrospective cohort study.

Capecitabine combined with immunotherapy as maintenance therapy improves survival in recurrent/metastatic nasopharyngeal carcinoma: a retrospective cohort study.

Journal: British journal of cancer

Published: April 16, 2025

Efficacy of metastasis-directed therapy in de novo metastatic nasopharyngeal carcinoma patients receiving chemo-immunotherapy and local regional radiotherapy: a multicenter retrospective study.

Efficacy of metastasis-directed therapy in de novo metastatic nasopharyngeal carcinoma patients receiving chemo-immunotherapy and local regional radiotherapy: a multicenter retrospective study.

Journal: BMC cancer

Published: February 16, 2025

Establishing M1 subdivision for de novo nasopharyngeal carcinoma patients receiving immuno-chemotherapy: A multicenter, retrospective cohort study.

Establishing M1 subdivision for de novo nasopharyngeal carcinoma patients receiving immuno-chemotherapy: A multicenter, retrospective cohort study.

Journal: Oral oncology

Published: August 17, 2024

Efficacy of local-regional radiotherapy in de novo metastatic nasopharyngeal carcinoma patients receiving chemo-immunotherapy: A multicenter, propensity score matching study.

Efficacy of local-regional radiotherapy in de novo metastatic nasopharyngeal carcinoma patients receiving chemo-immunotherapy: A multicenter, propensity score matching study.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: August 17, 2024

Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial.

Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial.

Journal: JAMA oncology

Published: March 24, 2022

Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy: A Phase 3 Randomized Clinical Trial.

Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy: A Phase 3 Randomized Clinical Trial.

Journal: JAMA oncology

Published: February 17, 2022

Assessment of Survival Model Performance Following Inclusion of Epstein-Barr Virus DNA Status in Conventional TNM Staging Groups in Epstein-Barr Virus-Related Nasopharyngeal Carcinoma.

Assessment of Survival Model Performance Following Inclusion of Epstein-Barr Virus DNA Status in Conventional TNM Staging Groups in Epstein-Barr Virus-Related Nasopharyngeal Carcinoma.

Journal: JAMA network open

Published: September 23, 2021

Prognostic and Predictive Value of Circulating Inflammation Signature in Non-Metastatic Nasopharyngeal Carcinoma: Potential Role for Individualized Induction Chemotherapy.

Prognostic and Predictive Value of Circulating Inflammation Signature in Non-Metastatic Nasopharyngeal Carcinoma: Potential Role for Individualized Induction Chemotherapy.

Journal: Journal of inflammation research

Published: March 07, 2021

A Scoring System Based on Nutritional and Inflammatory Parameters to Predict the Efficacy of First-Line Chemotherapy and Survival Outcomes for De Novo Metastatic Nasopharyngeal Carcinoma.

A Scoring System Based on Nutritional and Inflammatory Parameters to Predict the Efficacy of First-Line Chemotherapy and Survival Outcomes for De Novo Metastatic Nasopharyngeal Carcinoma.

Journal: Journal of inflammation research

Published: December 11, 2020

Showing 1-12 of 21

Last Updated: 09/26/2026